Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022

– Company to Webcast Investor Event on September 30th at 8:00 p.m. ET –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, during an oral poster session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022, on September 30, 2022. The Company recently announced positive results from the APOLLO-B study at the 18th International Symposium on Amyloidosis.

HFSA Presentation Details

• Primary Results from APOLLO-B, a Phase 3 Study of Patisiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy
  Oral Poster Session I
  Friday Sept. 30, 2022, 6:15 – 7:15 p.m. ET
  Lead Author: Mathew Maurer
• Exploratory Analyses from APOLLO-B, a Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
  Oral Poster Session I
  Friday Sept. 30, 2022, 6:15 – 7:15 p.m. ET
  Lead Author: Parag Kale